Does Treatment of Ocular Myasthenia Gravis With Early Immunosuppressive Therapy Prevent Secondarily Generalization and Should It Be Offered to All Such Patients?
- 1 March 2016
- journal article
- point counter-point
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Neuro-Ophthalmology
- Vol. 36 (1), 98-102
- https://doi.org/10.1097/wno.0000000000000270
Abstract
No abstract availableThis publication has 27 references indexed in Scilit:
- Ocular Myasthenia Gravis: Controversies and UpdatesCurrent Neurology and Neuroscience Reports, 2013
- Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-upZeitschrift für Neurologie, 2009
- Lifetime course of myasthenia gravisMuscle & Nerve, 2007
- The effect of prednisone on the progression from ocular to generalized myasthenia gravisJournal of the Neurological Sciences, 2004
- Immunotherapy of Ocular Myasthenia Gravis Reduces Conversion to Generalized Myasthenia GravisJournal of Neuro-Ophthalmology, 2003
- Development of Generalized Disease at 2 Years in Patients With Ocular Myasthenia GravisArchives of Neurology, 2003
- Ocular myasthenia gravis: response to long-term immunosuppressive treatment.Journal of Neurology, Neurosurgery & Psychiatry, 1997
- Beneficial Effects of Corticosteroids on Ocular Myasthenia GravisArchives of Neurology, 1996
- The natural course of myasthenia gravis: a long term follow up study.Journal of Neurology, Neurosurgery & Psychiatry, 1989
- Prognosis of ocular myastheniaAnnals of Neurology, 1983